Sign in
Not yet taking people in United StatesNo phase

Leveraging Telemedicine to Improve Guideline-Directed Medical Therapy Use and Outcomes Among Rural Patients With Heart Failure

Key facts

Who runs it
University of Michigan
Where
Ann Arbor and Plano, United StatesSee the 2 sites
Trial code
Status
Not yet recruiting
People taking part
600 people, planned
Starts
Dec 2026
Expected to end
Dec 2031
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Provider-to-provider telehealth GDMT titration support
  • Cellular-connected remote patient monitoring
Record updated
18 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Age > 18 years old
  • Hospitalization for heart failure (HF) with intravenous diuretic use, with randomization within 14 days of discharge
  • Residing in a rural area (home address in a rural area as defined by the Federal Office of Rural Health Policy)
  • Established outpatient care (cardiology or primary care physician) at the participating sites
  • Eligible to receive at least 2 of 4 guideline-directed medical therapy (GDMT) classes for HF with reduced or mildly reduced ejection fraction (HFrEF or HFmrEF; beta-blocker, ACE inhibitor/ARB/ARNi, MRA, SGLT2 inhibitor), or at least 1 of 3 GDMT classes for HF with preserved ejection fraction (HFpEF; ACE inhibitor/ARB/ARNi, MRA, SGLT2 inhibitor), and not on target doses of these medication classes
  • Able to communicate with the study team via telephone or videoconference for study-related assessments and follow-up

Who cannot take part

  • Stage D HF under consideration for or a recipient of advanced HF therapies, including left ventricular assist device (LVAD), heart transplant, or inotrope therapy
  • Potassium > 5.5 mmol/L
  • End-stage kidney disease or eGFR < 25 mL/min/1.73 m²
  • Discharge disposition to a nursing home, inpatient rehabilitation facility, or long-term care facility
  • Inability to provide informed consent
  • Pregnancy

Where in United States

  • University of MichiganAnn Arbor, United StatesContact: Ambarish Pandey, MDNot yet recruiting
  • Baylor Scott & White Cardiac Consultants - PlanoPlano, United StatesContact: Neil KeshvaniNot yet recruiting

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if a new way of adjusting heart failure medicines can improve health in adults with heart failure who live in rural areas. This study tests whether remotely helping local doctors safely raise these doses faster can improve health over the first 3 months after leaving the hospital.

Read full original descriptionShow less

The main questions it aims to answer are:

* Does the new approach help participants live longer, avoid needing a heart transplant or heart pump, stay out of the hospital for heart failure, and feel better day to day, over 6 months? * Do more participants take all their recommended heart failure medicines, at the best doses, by 6 months? * Does the new approach improve quality of life and daily activity, and how well does it work in everyday rural health care?

Participants will be placed by chance, like flipping a coin, into 1 of 2 groups: home monitoring alone or home monitoring plus medication optimization support. In the home monitoring alone group, participants' own doctors will manage their medicines as usual. In the medicine support group, heart failure specialists on the study team will use home readings and results from NT-proBNP blood tests, to send medicine advice to participants' own doctors. Researchers will compare the 2 groups to see if medicine support improves health and quality of life.

Participants will:

* Use a scale, blood pressure cuff, and activity tracker at home for 3 months * May have routine blood tests ordered by their own doctor about 2 and 6 weeks after joining, if they are in the medicine support group * Complete video or phone study visits when they join, at 3 months, and at 6 months * Answer questions about their heart failure symptoms and quality of life at each visit * Some participants may also be asked to take part in an interview about their experience.

The 2 groups in the trial

  • Remote patient monitoring + NT-proBNP & provider-to-provider supportTreatment being tested

    Participants receive a cellular-connected device kit (weight scale, blood pressure and heart rate monitor, and wrist-worn activity tracker) with remote monitoring for 90 days following enrollment. In addition, the study team recommends NT-proBNP and basic metabolic panel testing at weeks 2 and 6, which the participant's outpatient care team may obtain as part of routine clinical care. The study team reviews biometric and laboratory data at least weekly and delivers specific, evidence-based GDMT initiation and titration recommendations (drug, dose, titration schedule, and laboratory monitoring instructions) to the participant's outpatient care team through asynchronous electronic health record communication at one-to-two-week intervals throughout the 90-day titration period. At least one synchronous video or telephone consultation is offered, with additional consultations available at the provider's preference. The participant's outpatient care team implements all medication changes.

    Treatment: Provider-to-provider telehealth GDMT titration support and Cellular-connected remote patient monitoring

  • Remote patient monitoring (RPM) aloneExisting treatment, for comparison

    Participants receive the same cellular-connected device kit with remote monitoring for 90 days following enrollment. The study team may send safety alerts from remote monitoring to the participant's outpatient provider, without recommendations for GDMT up-titration. No recommendations for NT-proBNP testing and GDMT titration recommendations will be sent out by the study team. GDMT management, outpatient follow-up, and laboratory monitoring are delivered according to standard community practice by the participant's primary care provider or cardiologist.

    Treatment: Cellular-connected remote patient monitoring

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Leveraging Telemedicine to Improve Guideline-Directed Medical Therapy Use and Outcomes Among Rural Patients With Heart Failure - the RURAL-HF Trial
Record updated
18 November 2026